Alseres Pharmaceuticals (OTCMKTS:ALSE) versus Relmada Therapeutics (NASDAQ:RLMD) Financial Contrast

Alseres Pharmaceuticals (OTCMKTS:ALSE) and Relmada Therapeutics (NASDAQ:RLMD) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Valuation & Earnings

This table compares Alseres Pharmaceuticals and Relmada Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alseres Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Relmada Therapeutics	N/A	N/A	-$57.38 million	($1.45)	-4.19

Insider & Institutional Ownership

45.2% of Relmada Therapeutics shares are owned by institutional investors. 8.9% of Alseres Pharmaceuticals shares are owned by company insiders. Comparatively, 20.7% of Relmada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and price targets for Alseres Pharmaceuticals and Relmada Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alseres Pharmaceuticals	0	0	0	0	0.00
Relmada Therapeutics	1	1	3	1	2.67

Relmada Therapeutics has a consensus target price of $12.00, indicating a potential upside of 97.69%. Given Relmada Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Relmada Therapeutics is more favorable than Alseres Pharmaceuticals.

Profitability

This table compares Alseres Pharmaceuticals and Relmada Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alseres Pharmaceuticals	N/A	N/A	N/A
Relmada Therapeutics	N/A	-170.83%	-145.58%

Summary

Relmada Therapeutics beats Alseres Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

About Alseres Pharmaceuticals

Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson’s disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.

About Relmada Therapeutics

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.